Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 14, 2025
Healthcare Company Watkins-Conti Announces Publication of Positive Clinical Trial Results for FDA-Cleared Yōni.Fit
EIN Presswire
·
May 14, 2025
Self-administered device for stress urinary incontinence is unique alternative to surgery or pads EDMOND, OK, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- Watkins-Conti Products, Inc. ("Watkins-Conti"), a company that develops innovative solutions …
Jakub Leps Promoted to General Manager of Newsmatics Data Sciences
EIN Presswire
·
May 14, 2025
Leps to lead strategy and operations at the forefront of data innovation WASHINGTON, DC, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- Newsmatics, a news technology company known for its suite of innovative digital media products, is proud to …
Amblyopia (lazy eye) treatment expands in the digital therapeutics space with the launch of a new solution
EIN Presswire
·
May 14, 2025
NEW YORK, NY, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- A groundbreaking new treatment from Scottish startup Eyesight Electronics has enabled a patient, once classified as legally blind, to recover over 50 percent of their vision in just three …
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
GlobeNewswire
·
May 14, 2025
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 …
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 14, 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from …
Precipio Announces its Q1-2025 Financial Results
GlobeNewswire
·
May 14, 2025
NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain …
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting …
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
GlobeNewswire
·
May 14, 2025
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: …
SS Innovations Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “ …
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewswire
·
May 14, 2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the lives of …
Jasper Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
GlobeNewswire
·
May 14, 2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using …
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
GlobeNewswire
·
May 14, 2025
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to …
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean …
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using …
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
GlobeNewswire
·
May 14, 2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the …
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and …
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in …
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
GlobeNewswire
·
May 14, 2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in …
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …